Search Articles
WILMINGTON, Del. – Shareholders say Inhibitex, a biopharma company, is selling itself too cheaply to Bristol-Myers Squibb, for $2.5 billion or $26 a share.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.